Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $60.35 | Total: $301.75 |
| 1 | 10 | $51.12 | Total: $511.20 |
| 1 | 25 | $43.31 | Total: $1,082.75 |
| 1 | 50 | $36.92 | Total: $1,846.00 |
| 1 | 100 | $31.95 | Total: $3,195.00 |
Overview
Orelabrutinib (ICP-022) is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).
Chemical Properties
| Molecular Formula | C26H25N3O3 |
| Molecular Weight | 427.49 |
| CAS Numbers | 1655504-04-3 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)C1CCN(CC1)C(=O)C=C |
Storage and Handling
0C Short Term, -20C Long Term
References
Wei Xu, et al. Safety, Tolerability and Efficacy of Orelabrutinib, Once a Day, to Treat Chinese Patients with Relapsed or Refractory Chronic Lymphocytic LeukemiaSmall Cell Leukemia. Blood [2019] 134 [Supplement_1] 4319.